原发性乳腺鳞状细胞癌23例临床分析  

Primary squamous cell carcinoma of the breast： report of 23 cases

作　　者：吴梓政 连镇[1] 赵晶[1] 李利娟[1] 牛海飞 刘俊田[1] 

机构地区：[1]天津医科大学肿瘤医院乳腺二科,国家肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室,天津市肿瘤防治重点实验室,300060

出　　处：《中华普通外科杂志》2015年第9期723-725,共3页Chinese Journal of General Surgery

基　　金：天津市应用基础与前沿技术研究计划（13JCQNJC12700,13JCYBJC24200）

摘　　要：目的探讨原发性乳腺鳞状细胞癌的临床病理特征及预后。方法对天津医科大学肿瘤医院1984--2013年收治的23例原发性乳腺鳞状细胞癌患者临床及病理资料进行回顾性分析。结果原发性乳腺鳞状细胞癌发病率低，约占同期乳腺癌患者的0．06％。患者全部为女性，发病年龄28～87岁，中位年龄49岁；肿瘤平均大小为4．5cm。9例患者就诊时伴有淋巴结转移（39．1％）。雌激素受体（estrogen receptor，ER）、孕激素受体（progesterone receptor，PR）、人表皮生长因子受体（human epithelial growth factor receptor 2，HER-2）阳性率分别为13．0％（3／23）、4．3％（1／23）、0（0／20）。8例患者在随访5～36个月后出现复发或转移，1例患者入院时伴远处转移。9例出现复发或转移的患者中，肺转移较为常见（77．7％），6例死亡。结论原发性乳腺鳞状细胞癌是一种少见的化生性癌，侵袭性强、受体阴性率高，且治疗后早期容易出现复发或转移，预后差。Objective To investigate the clinical and pathologic features of squamous cell carcinoma of the breast. Methods The clinical and pathologic data of 23 squamous cell carcinoma of the breast patients admitted between 1984 and 2013 to Tianjin Medical University Cancer Hospital was analyzed retrospectively. Results Primary squamous cell carcinoma of the breast was a very rare tumor accounting for 0. 06% of all breast cancers. All of the 23 patients were females aged 28 years to 87 years（ median age 49 years）. Average tumor size was 4. 5 cm. 9 patients suffered from lymph node metastasis at admission （39. 1% ）. The positive rates of estrogen receptor （ER）, progesterone receptor （PR） and human epidermal growth factor receptor 2 （ HER-2 ） were 13. 6% （ 3/23 ）, 4. 5% （ 1/23 ） and 0 （ 0/20 ） respectively. With a follow-up time varying from 5 months to 36 months recurrence or metastasis were found in 8 patients, and another 1 patient was found having distant metastasis at admission. Lung metastasis （7/9） was most common. 6 patients died. Conclusions Squamous cell carcinoma of the breast is highly invasive, with low rate of positive receptors and early distant metastasis or recurrence after operation,and poor patients＇ survival.

关 键 词：乳腺肿瘤 病理学 临床 预后 

分 类 号：R737.9[医药卫生—肿瘤]